Subscribe
shutterstock_1826152031_lev_radin
Lev Radin / Shutterstock.com
24 August 2021Big PharmaAlex Baldwin

Regeneron asks court to dismiss COVID-19 tech patent suit

Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
US court backs Sanofi and Regeneron in Amgen suit
29 August 2019   A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
US court backs Sanofi and Regeneron in Amgen suit
29 August 2019   A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More on this story

Big Pharma
A deep dive into Regeneron v Kymab
8 March 2021   On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
US court backs Sanofi and Regeneron in Amgen suit
29 August 2019   A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
PTAB grants IPR of Regeneron Eylea patents
11 November 2021   The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York